Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin visual toxicity: evolution and dose dependence.

K Malmgren1, E Ben-Menachem, L Frisén

  • 1Institute of Clinical Neuroscience, Department of Neurology, Sahlgrenska Hospital, Göteborg, Sweden. kristina.malmgren@sahlgrenska.se

Epilepsia
|May 31, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.

Acta neurologica Scandinavica·2018
Same author

The effect of a multifaceted postoperative nausea and vomiting reduction strategy on prophylaxis administration amongst higher-risk adult surgical patients.

Anaesthesia and intensive care·2018
Same author

Wearables in epilepsy and Parkinson's disease-A focus group study.

Acta neurologica Scandinavica·2017
Same author

Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.

Journal of neurology·2017
Same author

Psychosocial outcome in adult men born with hypospadias.

Journal of pediatric urology·2017
Same author

Sexuality and fertility in men with hypospadias; improved outcome.

Andrology·2016

Vigabatrin (VGB) treatment in epilepsy patients is strongly linked to visual field defects (VFDs), with prevalence increasing with cumulative dose. These VFDs appear irreversible and often progressive, even in patients not exposed to VGB.

Area of Science:

  • Neuro-ophthalmology
  • Epilepsy Research
  • Pharmacovigilance

Background:

  • Epilepsy management often involves medications with potential side effects.
  • Vigabatrin (VGB) is an anti-epileptic drug with known risks of visual field defects (VFDs).

Purpose of the Study:

  • To determine the prevalence and prognosis of VFDs in epilepsy patients treated with VGB.
  • To explore the relationship between VFDs and cumulative VGB dose.
  • To characterize the progression of VFDs over time.

Main Methods:

  • A cohort of 155 epilepsy patients underwent full-field Goldmann perimetry (GP).
  • 99 patients had received VGB treatment; GPs were re-evaluated by a blinded examiner.
  • Duration and cumulative VGB dose were correlated with perimetric results.

Related Experiment Videos

Main Results:

  • 16% of patients had VFDs; 19% of VGB-treated patients vs. 11% of untreated patients.
  • VFD prevalence significantly increased with cumulative VGB dose (4% for <1kg to 75% for 3-5kg).
  • VFDs were found to be irreversible and progressive in a substantial percentage of VGB-treated patients over 2-10 years.

Conclusions:

  • A strong association exists between VFDs and VGB treatment duration and dose.
  • VFDs in VGB toxicity are largely irreversible and can be progressive.
  • Similar VFDs may occur in non-VGB-exposed patients; a model for VFD evolution is proposed.